← Back to screener

Fulgent Genetics, Inc. FLGT

Rank #1638 · Nasdaq · $0.6B market cap
Audited by DELOITTE & TOUCHE LLP, no going-concern flag in the latest filing.
Score
45.2
P/E
-3.5
P/B
0.52
ROE
-14.8%
Op. Margin
-67.6%
Debt Ratio
8%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★★★☆☆
Average

P/E -3.5x, P/B 0.52x. Ranks in the top 49% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -14.8%. Ranks in the top 84% of the universe.

Safety ★★★★★
Excellent

Debt ratio 8%. Ranks in the top 9% of the universe. Under 100% is generally considered a safe level.

Growth ★☆☆☆☆
Poor

Revenue decline of 53.3% year over year. Ranks in the top 98% of the universe.

Safety is the relative strength · Profitability is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2016$0.0B$-0.0B$-0.0B$0.0B-77.535
2017$0.0B$0.0B$-0.0B$0.0B5.069
2018$0.0B$-0.0B$-0.0B$0.1B-18.66
2019$0.0B$-0.0B$-0.0B$0.1B-23.75
2020$0.0B$-0.0B$-0.0B$0.1B-1.312
2021$0.0B$-0.0B$-0.0B$0.6B-1.323
2022$0.4B$0.3B$0.2B$1.2B68.810
2023$1.0B$0.7B$0.5B$1.3B68.19
2024$0.6B$0.2B$0.1B$1.1B28.89
2025$0.3B$-0.2B$-0.2B$1.1B-67.68

← See the full screener